BioCentury
ARTICLE | Product Development

COVID-19: API supply on the line

A map of API manufacturing sites worldwide

March 4, 2020 2:14 AM UTC

Avoiding supply chain problems will be front and center for biopharmas as COVID-19 spreads. Restrictions on transport of active pharmaceutical ingredients are likely to hit manufacturing of approved drugs, which could limit supply, as well as experimental drugs for clinical trials.

Among the nearly 10,000 drug manufacturing facilities registered with FDA, 1,922 manufacture APIs, more than half of which are located in the U.S., China or India. ...